Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0PN3P
|
||||
Former ID |
DNC007949
|
||||
Drug Name |
H-Aba-ala-Gly-Phe-leu-OH
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C30H39N7O6S
|
||||
Canonical SMILES |
CC(C)CC(C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)C(C)NC<br />(=O)C(CC2=CC3=C(C=C2)N=C(S3)N)N
|
||||
InChI |
1S/C30H39N7O6S/c1-16(2)11-23(29(42)43)36-28(41)22(13-18-7-5-4-6-8-18)35-25(38)15-33-26(39)17(3)34-27(40)20(31)12-19-9-10-21-24(14-19)44-30(32)37-21/h4-10,14,16-17,20,22-23H,11-13,15,31H2,1-3H3,(H2,32,37)(H,33,39)(H,34,40)(H,35,38)(H,36,41)(H,42,43)/t17-,20-,22-,23-/m0/s1
|
||||
InChIKey |
VLIQMZUUPDOVAM-NWZJSZKRSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Delta-type opioid receptor | Target Info | Inhibitor | [1] | |
Mu-type opioid receptor | Target Info | Inhibitor | [1] | ||
KEGG Pathway | cGMP-PKG signaling pathway | ||||
Sphingolipid signaling pathway | |||||
Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | |||||
Estrogen signaling pathway | |||||
Morphine addiction | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Enkephalin release | |||||
Opioid proenkephalin pathway | |||||
Opioid proopiomelanocortin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
Pathway Interaction Database | IL4-mediated signaling events | ||||
Reactome | Peptide ligand-binding receptors | ||||
G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
G alpha (i) signalling events | |||||
WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
Peptide GPCRs | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP69:TCR Signaling Pathway | |||||
Opioid Signalling | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.